Medline (MDLN Proposed) is on the market’s mind this week. Private equity-backed Medline is in focus with its $5 billion IPO – the biggest deal of the year. Medline, based in the Chicago suburb of Northfield, Illinois, is the world’s largest provider of medical-surgical products and supply chain solutions. The company is profitable.
The Medline deal consists of 179 million shares – all offered by the company – at a price range of $26.00 to $30.00 – to raise $5.01 billion, if priced at the $28.00 mid-point of its range.
Medline’s IPO is set to price Tuesday night, Dec.16, 2025, to trade Wednesday, Dec. 17, on the NASDAQ.
Goldman Sachs, Morgan Stanley, BofA Securities and J.P. Morgan are the global coordinators and the joint lead managers of Medline’s IPO. More than 40 investment banks are involved in Medline’s deal as either joint book-runners or co-managers.
Medline, founded in 1966, intends to use most of the IPO proceeds to repay $4 billion in debt. Its total debt stood at about $16.8 billion, as of Sept. 27, 2025, according to the prospectus.
Andersen Group (ANDG Proposed), a profitable tax and financial services advisory firm founded in 2002 by partners and managers of the former Arthur Andersen, is also on tap this week with its proposed $165 million IPO. San Francisco-based Andersen Group’s IPO is set to price Tuesday night, Dec. 16, to trade Wednesday, Dec. 17, on the New York Stock Exchange.
Morgan Stanley and UBS Investment Bank are leading the joint book-running team for Andersen’s IPO.